Welcome to our dedicated page for BPSR news (Ticker: bpsr), a resource for investors and traders seeking the latest updates and insights on BPSR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BPSR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BPSR's position in the market.
Organicell Regenerative Medicine (OTCMKTS: BPSR) has partnered with Oklahoma State University to assess the efficacy of its product, Zofin™, in treating respiratory diseases from viral infections, including COVID-19. This follows a prior agreement with the CDC to explore Zofin™'s anti-inflammatory properties in influenza models. Zofin™ is an acellular therapy derived from human amniotic fluid, containing over 300 growth factors and cytokines. The study addresses the urgent need for safe, effective treatments for viruses capable of causing pandemics, contributing to ongoing research in regenerative medicine.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) has formed a Material Cooperative Research and Development Agreement with the CDC to study the effectiveness of its compound Zofin™ against influenza. Influenza poses significant health risks, with the CDC estimating 39-55 million illnesses and over 60,000 deaths annually in the U.S. Zofin, derived from human amniotic fluid, may help mitigate inflammatory responses associated with viral infections. The CDC will conduct tests using established models, while Organicell continues its trials for respiratory failure related to COVID-19.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) announced the publication of a peer-reviewed case report in 'Frontiers in Medicine', detailing Zofin's clinical outcomes for three critically ill COVID-19 patients. The report highlights Zofin's safety and potential efficacy as a treatment for respiratory failure. All patients received Zofin alongside standard care and were monitored for 28 days post-treatment. The case report marks a significant milestone in Organicell's research efforts in regenerative therapies.
Organicell Regenerative Medicine (OTCMKTS: BPSR) has received FDA approval for its Investigational New Drug (IND) application to initiate a clinical trial of Zofin™. This trial aims to evaluate the safety and potential efficacy of Zofin™, a biologic therapy developed for patients with chronic obstructive pulmonary disease (COPD). The double-blinded, placebo-controlled phase I/II trial will utilize intravenous infusion of Zofin™. COPD affects 16 million diagnosed patients in the U.S., with no current cure available.
Organicell Regenerative Medicine (OTCMKTS: BPSR) will host a live online discussion on COVID-19 long-haulers on January 13th at 7 P.M. EST. Experts will discuss the extensive impact of long-term symptoms affecting these patients and introduce Organicell's investigational therapeutic, Zofin™, which contains over 300 growth factors, aimed at addressing their unmet healthcare needs. The event features Chief Science Officer Mari Mitrani interviewing key medical professionals to highlight current gaps in therapy for long-haulers.
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) announced that its therapeutic drug Zofin™ was highlighted in the Wall Street Journal and BioSpace for potential benefits to COVID-19 long-haulers. Zofin™, a biologic derived from perinatal sources, is in a Phase I/II trial for treating moderate to severe COVID-19. The FDA granted expanded access for Zofin™, allowing treatment for mild to moderate COVID-19 patients. The company aims to initiate a Phase IIb trial in Q1 2021, contingent on successful outcomes and regulatory approvals.
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) has announced it is current in its SEC reporting obligations under the Securities Exchange Act. Following the filing of its Quarterly Report on Form 10-Q for the quarter ending July 31, 2020, on December 18, 2020, the company is back on track with its SEC filings, having been non-compliant since 2017. Organicell specializes in developing innovative regenerative therapies derived from perinatal sources. Their products retain natural microRNAs, supporting their commitment to biological therapeutics.